Jean-Claude Chermann

This inventor holds 27 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignees: Institut Pasteur, Centre National De La Recherche Scientifique, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 1981-2013.

USPTO Granted Patents = 27

% Patents Active = 96.3

CIPO Patents = 1

EPO Patents = 2

Average Co-Inventor Count = 8.4

ph-index = 5

Forward Citations = 246(Granted Patents)

Location History:

Garches, FR (1985)
Elancourt, FR (1981 - 2009)
Cassis, FR (2007 - 2013)

Company Filing History:

Centre National De La Recherche Scientifique

patents

3 out of 3,688

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4. 2 out of 338

Agence Nationale De Valorisation De La Recherche (Anvar)

patents

5. 2 out of 4

Cabinet Harle & Phelip

patents

6. 2 out of 128

Institut National De La Recherche Scientifique

patents

7. 1 out of 46

Agence Nationale De Valorisation De La Recherche

patents

8. 1 out of 1,217

The United States of America as Represented by the Department of Health

patents

9. 1 out of 2,202

The United States of America as Represented by the Secretary of

12. 5 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1981-2013

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8507196 - Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1 (2013-08-13),

2. 8329396 - Cloned DNA sequences hybridizable with genomic RNA of lymphadenopathy associated virus (LAV) (2012-12-11),

3. 7626013 - HIV-1 DNA fragments that hybridize to genomic HIV-1DNA (2009-12-01),

4. 7585619 - Method for detecting human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity (2009-09-08),

5. 7306798 - Immunoglobulin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same (2007-12-11),

6. 7232654 - DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1) (2007-06-19),

7. 7217508 - Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1) (2007-05-15),

8. 7205102 - Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA (2007-04-17),

9. 7122188 - Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1 (2006-10-17),

10. 6627395 - Methods for the propagation, isolation, identification, and preparation of human immunodeficiency virus type 1 (HIV-1) (2003-09-30),

11. 6600023 - Antibody directed against HIV-1 P25 antigen (2003-07-29),

12. 6440657 - Nucleic acids and peptides of human immunodeficiency virus type (HIV-1) (2002-08-27),

13. 6428952 - Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies (2002-08-06),

14. 6395495 - Methods and kits for detecting antibodies against an HIV variant (2002-05-28),

15. 5843638 - Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1). (1998-12-01),

Title: Jean-Claude Chermann: Pioneering French Inventor

Introduction: Jean-Claude Chermann, a distinguished inventor hailing from Cassis, France, has made significant contributions to the field of innovation with his groundbreaking work.

Latest Patents: Jean-Claude Chermann holds several patents in the areas of biotechnology and pharmaceuticals, showcasing his expertise and creativity in these fields.

Career Highlights: Throughout his illustrious career, Chermann has been recognized for his innovative approach to problem-solving and his ability to translate ideas into tangible inventions that have had a lasting impact on society.

Collaborations: Chermann has collaborated with leading research institutions and pharmaceutical companies, fostering a culture of innovation and knowledge-sharing within the industry.

Conclusion: Jean-Claude Chermann's dedication to pushing the boundaries of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a trailblazing inventor in the global scientific community.